Log in

Relevant bibliographies by topics / Failed bid / Journal articles

To see the other types of publications on this topic, follow the link: Failed bid.

Journal articles on the topic 'Failed bid'

Author: Grafiati

Published: 4 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Failed bid.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kassens-Noor, Eva, and John Lauermann. "Mechanisms of policy failure: Boston’s 2024 Olympic bid." Urban Studies 55, no. 15 (2017): 3369–84. http://dx.doi.org/10.1177/0042098017740286.

Full text

Abstract:

Planning for mega-events such as the Olympics is at a turning point. There has been a power shift in the relationship between cities and the International Olympic Committee towards the former. This shift is based on the emergence of anti-bid opposition movements; the increasing complexity of bidding; demands for locally relevant legacies; and a changing political economic relationship between citizens, city governments and sports federations. Our paper draws on a long-term study of Boston’s failed bid to host the 2024 Summer Olympics, based on an ethnography within the bidding corporation and

APA, Harvard, Vancouver, ISO, and other styles

2

Rosado Marzán, César F. "PIRATES OF THE CARIBBEAN: SEIU'S FAILED BID IN PUERTO RICO." WorkingUSA 12, no. 2 (2009): 235–47. http://dx.doi.org/10.1111/j.1743-4580.2009.00231.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

van Dijk, Terry, and Gerd Weitkamp. "Power in Dreams? The Spatial Effects of Chicago's Failed Olympic Bid." International Planning Studies 19, no. 2 (2013): 111–31. http://dx.doi.org/10.1080/13563475.2013.830681.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Atif, Salman. "Appointed Person rejects appeal that two DG decisions are inconsistent." Journal of Intellectual Property Law & Practice 15, no. 1 (2019): 5–7. http://dx.doi.org/10.1093/jiplp/jpz155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

McKay, Huw. "Tokyo's Ultimately Failed Bid for First-Tier International Financial Center Status: Why Did It Fall Short?" Asian Economic Papers 13, no. 3 (2014): 1–25. http://dx.doi.org/10.1162/asep_a_00287.

Full text

Abstract:

Tokyo's bid to ascend to the very top tier of international financial centers (IFCs) was ultimately unsuccessful. This paper argues that to overcome the large disadvantages of being a latecomer, the IFC goal must be elevated above other competing objectives so that the necessary intermediate steps can be achieved in timely fashion. The most important specific failing was the inability of the Japanese yen to become a major international vehicle currency. With a sharper and earlier policy focus, particularly in the area of yen trade invoicing, Tokyo's bid for first tier IFC status would have bee

APA, Harvard, Vancouver, ISO, and other styles

6

Sutton, Vivien R., Joanne E. Davis, Michael Cancilla, et al. "Initiation of Apoptosis by Granzyme B Requires Direct Cleavage of Bid, but Not Direct Granzyme B–Mediated Caspase Activation." Journal of Experimental Medicine 192, no. 10 (2000): 1403–14. http://dx.doi.org/10.1084/jem.192.10.1403.

Full text

Abstract:

The essential upstream steps in granzyme B–mediated apoptosis remain undefined. Herein, we show that granzyme B triggers the mitochondrial apoptotic pathway through direct cleavage of Bid; however, cleavage of procaspases was stalled when mitochondrial disruption was blocked by Bcl-2. The sensitivity of granzyme B–resistant Bcl-2–overexpressing FDC-P1 cells was restored by coexpression of wild-type Bid, or Bid with a mutation of its caspase-8 cleavage site, and both types of Bid were cleaved. However, Bid with a mutated granzyme B cleavage site remained intact and did not restore apoptosis. Bi

APA, Harvard, Vancouver, ISO, and other styles

7

Bandyopadhyay, Kausik. "In search of an Olympic legacy: the story of India's failed Olympic bid." Sport in Society 17, no. 5 (2013): 609–16. http://dx.doi.org/10.1080/17430437.2013.834619.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Bussel, James B., Allison M. Schindler, and Elliott B. Grossbard. "R935788: A Phase II, Single Center, Open Label, Efficacy and Safety, Ascending Dose, Pilot Study for the Treatment of Adult Immune Thrombocytopenic Purpura (ITP)." Blood 110, no. 11 (2007): 1310. http://dx.doi.org/10.1182/blood.v110.11.1310.1310.

Full text

Abstract:

Abstract Syk kinase is central to FcR and B-cell signaling in inflammatory cells. By inhibiting syk, and thereby IgG signaling, R788 (a small molecule prodrug for biologically active R406), inhibits the downstream activation of mast cells, macrophages and B-cells. (Braselmann S. Pharm Exp Ther. 2006). Preclinical study showed that R788 minimized thrombocytopenia in mice treated with anti-platelet antibodies (Crow, A.R. Blood 2005). In this study, adult, refractory ITP patients (pts) were treated with escalating doses of R788 in cohorts of ≥3 pts to evaluate safety and efficacy. After a cohort

APA, Harvard, Vancouver, ISO, and other styles

9

Armour, Ian D. "Hungary's Failed Bid to Control Serbia: The Trial of Prince Alexander Karadordević, 1868–1871." International History Review 31, no. 4 (2009): 740–70. http://dx.doi.org/10.1080/07075332.2009.9641171.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Chini, C., I. Proserpio, M. E. Giudici, G. Pinotti, B. Pozzi, and C. Capella. "Very long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated tissue (MALT) following Helicobacter pylori (Hp) eradication therapy." Journal of Clinical Oncology 24, no. 18_suppl (2006): 7531. http://dx.doi.org/10.1200/jco.2006.24.18_suppl.7531.

Full text

Abstract:

7531 Background: Hp infection plays a decisive role in the pathogenesis of low-grade gastric MALT lymphoma and eradication therapy has become a widely accepted initial treatment of stage I disease. The aim of this study was to evaluate the long term outcome of patients (pts) with localized gastric MALT lymphoma exclusively treated with Hp eradication therapy. Methods: a prospective series of 62 newly diagnosed IE gastric MALT lymphoma pts (29M/33F) with median age of 63 years (range 27–87), referred to our department from June 1991 to January 2004 were evaluable for the study. Diagnosis was hi

APA, Harvard, Vancouver, ISO, and other styles

11

Yuan, Shuying. "A miraculous revitalization of Japan? A comparative analysis of the 1964 Tokyo Olympic Games, the failed 2016 host city bid and the successful 2020 bid." Asia Pacific Journal of Sport and Social Science 2, no. 3 (2013): 198–213. http://dx.doi.org/10.1080/21640599.2013.861665.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Karp, Judith E., Jeffrey E. Lancet, Scott H. Kaufmann, et al. "Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial." Blood 97, no. 11 (2001): 3361–69. http://dx.doi.org/10.1182/blood.v97.11.3361.

Full text

Abstract:

R115777 is a nonpeptidomimetic enzyme-specific inhibitor of farnesyl protein transferase (FT) that was developed as a potential inhibitor of Ras protein signaling, with antitumor activity in preclinical models. This study was a phase 1 trial of orally administered R115777 in 35 adults with poor-risk acute leukemias. Cohorts of patients received R115777 at doses ranging from 100 mg twice daily (bid) to 1200 mg bid for up to 21 days. Dose-limiting toxicity occurred at 1200 mg bid, with central neurotoxicity evidenced by ataxia, confusion, and dysarthria. Non–dose-limiting toxicities included rev

APA, Harvard, Vancouver, ISO, and other styles

13

Gerds, Aaron T., Michael R. Savona, Bart L. Scott, et al. "Results of PAC203: A Randomized Phase 2 Dose-Finding Study and Determination of the Recommended Dose of Pacritinib." Blood 134, Supplement_1 (2019): 667. http://dx.doi.org/10.1182/blood-2019-129293.

Full text

Abstract:

Background: Pacritinib (PAC), an oral JAK2/IRAK 1 inhibitor, has demonstrated clinical benefit in myelofibrosis (MF) patients in two prior Phase 3 studies (PERSIST-1, PERSIST-2). PAC203 is a randomized Phase 2 dose-finding study in patients with MF who were intolerant of or failed to benefit from ruxolitinib. Herein, we describe the results, including pharmacokinetic and pharmacodynamic (PK/PD) analyses, used to identify the recommended dose of PAC for further study. Methods: Patients with DIPSS intermediate-1, -2, or high-risk MF who were intolerant of ruxolitinib (treatment ≥28 days complica

APA, Harvard, Vancouver, ISO, and other styles

14

Nordquist, Luke T., Neal D. Shore, Johann S. De Bono, et al. "Objective response of the dual CYP17-Lyase (L) inhibitor / androgen receptor (AR) antagonist, VT-464, in patients with CRPC." Journal of Clinical Oncology 34, no. 2_suppl (2016): 273. http://dx.doi.org/10.1200/jco.2016.34.2_suppl.273.

Full text

Abstract:

273 Background: VT-464 is an oral, CYP17-L inhibitor and non-clinically an antagonist of the AR and its variants associated with clinical resistance to enzalutamide (ENZ) and abiraterone (AA). The safety, tolerability and initial pharmacodynamic effects (tumor responses, PSA and testosterone (T) decreases) of VT-464 given without steroid supplementation either bid with food or QD at night with dinner were evaluated in the Phase (Ph) 1/2 studies INO-VT-464-CL-001 (NCT02012920) and INO-VT-464-CL-004 (NCT02361086), respectively. Patients were either treatment-naïve (TN), or had failed AA or ENZ o

APA, Harvard, Vancouver, ISO, and other styles

15

Cullen, Sean P., Colin Adrain, Alexander U. Lüthi, Patrick J. Duriez, and Seamus J. Martin. "Human and murine granzyme B exhibit divergent substrate preferences." Journal of Cell Biology 176, no. 4 (2007): 435–44. http://dx.doi.org/10.1083/jcb.200612025.

Full text

Abstract:

The cytotoxic lymphocyte protease granzyme B (GzmB) can promote apoptosis through direct processing and activation of members of the caspase family. GzmB can also cleave the BH3-only protein, BID, to promote caspase-independent mitochondrial permeabilization. Although human and mouse forms of GzmB exhibit extensive homology, these proteases diverge at residues predicted to influence substrate binding. We show that human and mouse GzmB exhibit radical differences in their ability to cleave BID, as well as several other key substrates, such as ICAD and caspase-8. Moreover, pharmacological inhibi

APA, Harvard, Vancouver, ISO, and other styles

16

Sandborn, W. J., M. C. Dubinsky, J. Torres, et al. "DOP61 Impact of prior tumour necrosis factor inhibitor failure and prior corticosteroid use on the maintenance of efficacy of tofacitinib following dose reduction in patients with Ulcerative Colitis who were in stable remission: 6-month data from the double-blind, randomised RIVETING study." Journal of Crohn's and Colitis 15, Supplement_1 (2021): S096—S097. http://dx.doi.org/10.1093/ecco-jcc/jjab073.100.

Full text

Abstract:

Abstract Background Tofacitinib is an oral, small molecule JAK inhibitor for the treatment of ulcerative colitis (UC). RIVETING (NCT03281304) is an ongoing, double-blind, randomised, parallel-group study designed to evaluate the efficacy and safety of dose reduction to tofacitinib 5 mg twice daily (BID) vs remaining on 10 mg BID in patients (pts) with UC in stable remission on tofacitinib 10 mg BID maintenance therapy. Eligible pts had received tofacitinib 10 mg BID for ≥2 consecutive years in an open-label, long-term extension (OLE) study (NCT01470612), and had been in stable remission for ≥6

APA, Harvard, Vancouver, ISO, and other styles

17

Hutchinson, Erin. "Ivan Denisovich on Trial: Soviet Writers, Russian Identity, and Solzhenitsyn’s Failed Bid for the 1964 Lenin Prize." Kritika: Explorations in Russian and Eurasian History 22, no. 1 (2021): 75–106. http://dx.doi.org/10.1353/kri.2021.0003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Cortes, J. E., H. J. Khoury, S. Corm, et al. "Subcutaneous omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients (Pts) with the T315I mutation: Data from an ongoing phase II/III trial." Journal of Clinical Oncology 27, no. 15_suppl (2009): 7008. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.7008.

Full text

Abstract:

7008 Background: Omacetaxine (OM), a first-in-class cetaxine shows clinical activity against Ph+ CML with a mechanism independent of tyrosine kinase inhibition. Currently available tyrosine kinase inhibitors (TKIs) have no activity against T315I. Methods: Adult Pts with T315I+ CML following TKI failure received OM induction at 1.25 mg/m2 subcutaneous (SC) twice daily (BID) for 14 days every 28 days followed by maintenance at 1.25 mg/m2 SC BID for 7 days every 28 days (maintenance after at least one induction cycle and achievement of hematologic response). Results: 66 pts (39 chronic [CP], 16 a

APA, Harvard, Vancouver, ISO, and other styles

19

Dieng, Aissata, Jie He, and Thomas G. Poder. "Web Comparison of Three Contingent Valuation Techniques in Women of Childbearing Age: The Case of Ovulation Induction in Quebec." Interactive Journal of Medical Research 9, no. 1 (2020): e13355. http://dx.doi.org/10.2196/13355.

Full text

Abstract:

Background In Canada, 11.5% to 15.7% of couples suffer from infertility. Anovulation, or failed ovulation, is one of the main causes of infertility in women. In Quebec, the treatment for ovulation induction and other services related to assisted reproductive technology (ART) have been partially reimbursed by the government since 2010. Objective This study aimed to compare the willingness to pay (WTP) of women of childbearing age to receive drug treatment in the event of failed ovulation according to 3 different contingent valuation methods. Methods The following elicitation techniques were use

APA, Harvard, Vancouver, ISO, and other styles

20

Fujiwara, Y., N. Yamamoto, K. Yamada, et al. "A phase I and pharmacokinetic/pharmacodynamic study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in Japanese patients with solid tumor." Journal of Clinical Oncology 25, no. 18_suppl (2007): 14015. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.14015.

Full text

Abstract:

14015 Background: Vorinostat (Zolinza™), a potent inhibitor of histone deacetylase (HDAC), induces tumor growth inhibition, differentiation, and apoptosis in vitro. Increasing evidence has revealed clinical activity of vorinostat in patients (pts) with various types of cancer including cutaneous T-cell lymphoma. Methods: Japanese pts with solid tumor who failed standard therapy were enrolled in a single institution, National Cancer Center hospital, Phase I study. Pts were dosed with vorinostat BID for 14 consecutive days followed by 7 day-rest starting at 100 mg and escalated by 100 mg BID unt

APA, Harvard, Vancouver, ISO, and other styles

21

Wang, Gui-Qiang, Eva Wieckowski, Leslie A. Goldstein, et al. "Resistance to Granzyme B-mediated Cytochrome c Release in Bak-deficient Cells." Journal of Experimental Medicine 194, no. 9 (2001): 1325–38. http://dx.doi.org/10.1084/jem.194.9.1325.

Full text

Abstract:

Granzyme B (GrB), a serine protease with substrate specificity similar to the caspase family, is a major component of granule-mediated cytotoxicity of T lymphocytes. Although GrB can directly activate caspases, it induces apoptosis predominantly via Bid cleavage, mitochondrial outer membrane permeabilization, and cytochrome c release. To study the molecular regulators for GrB-mediated mitochondrial apoptotic events, we used a CTL-free cytotoxicity system, wherein target cells are treated with purified GrB and replication-deficient adenovirus (Ad). We report here that the Bcl-2 proapoptotic fam

APA, Harvard, Vancouver, ISO, and other styles

22

Fang, Yong, Hongming Pan, Shun Lu, Hong Hu, and Qin Lu. "A phase I study to evaluate safety, tolerability, pharmacokinetics, and preliminary antitumor activity of TQ-B3101." Journal of Clinical Oncology 38, no. 15_suppl (2020): e21705-e21705. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e21705.

Full text

Abstract:

e21705 Background: TQ-B3101 is a novel compound, which deacetylated metabolite targets to receptor tyrosine kinases including ALK, ROS1 and MET. Preclinical studies showed TQ-B3101 had a better Inhibition activity and duration compared with equimolar crizotinib. Methods: Patients (pts) with advanced solid tumor failed to standard therapy were enrolled into dose escalation and expansion cohorts. TQ-B3101 was orally administered at doses of 100~300mg QD or 200~350mg BID in a 28-day cycle, then received the same dose until disease progression or intolerable toxicity. Dose escalation was based on

APA, Harvard, Vancouver, ISO, and other styles

23

Wetzler, M., A. Hellmann, J. Lipton, et al. "Subcutaneous omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients resistant or intolerant to two or more tyrosine kinase inhibitors (TKIs): Data from an ongoing phase II trial." Journal of Clinical Oncology 27, no. 15_suppl (2009): 7027. http://dx.doi.org/10.1200/jco.2009.27.15_suppl.7027.

Full text

Abstract:

7027 Background: Omacetaxine (OM), a first-in-class cetaxine, shows clinical activity against Ph+ CML with a mechanism of action independent to tyrosine kinase inhibition. Patients (Pts) who have failed multiple TKIs may benefit from an alternative therapy for CML. Methods: Pts include adult CML following resistance or intolerance to at least 2 TKIs. T315I+ Pts are enrolled in a separate trial. Pts receive OM induction at 1.25 mg/m2 subcutaneous (SC) BID for 14 days every 28 days followed by maintenance at 1.25 mg/m2 SC BID for 7 days every 28 days (maintenance after at least one induction cyc

APA, Harvard, Vancouver, ISO, and other styles

24

Ma, Yuxiang, Nong Yang, Su Li, et al. "A phase I, dose-escalation and expansion study of TQ-B3139, a novel ALK TKI, in Chinese ALK or ROS1 positive advanced non-small cell lung cancer (NSCLC)." Journal of Clinical Oncology 38, no. 15_suppl (2020): 9585. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.9585.

Full text

Abstract:

9585 Background: TQ-B3139 is a novel ALK inhibitor with activity 3-7 folds higher than Crizotinib against a broad range of ALK mutations. This phase I study (NCT03099330) is to investigate the safety, and determine the recommended phase II dose (RP2D), and pharmacokinetic (PK), clinical efficacy of TQ-B3139 in Chinese NSCLC patients. Methods: Patients with advanced NSCLC and failed at least one systemic anti-cancer treatment were enrolled. TQ-B3139 was administered orally from 50mg~100mg qd and 200, 300, 400, 500, 600 and 800mg bid, using a PK-guided modified Fibonacci 3+3 dose escalation desi

APA, Harvard, Vancouver, ISO, and other styles

25

ALBERTS, HEIKE C. "Berlin's Failed Bid to Host the 2000 Summer Olympic Games: Urban Development and the Improvement of Sports Facilities." International Journal of Urban and Regional Research 33, no. 2 (2009): 502–16. http://dx.doi.org/10.1111/j.1468-2427.2009.00847.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kwak, Jae-Yong, Hawk Kim, Jeong A. Kim, et al. "Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial." Blood 126, no. 23 (2015): 476. http://dx.doi.org/10.1182/blood.v126.23.476.476.

Full text

Abstract:

Abstract Background Radotinib is a second generation BCR-ABL1 tyrosine kinase inhibitor (TKI) developed by IL-YANG Pharm. Co., Ltd (Seoul, South Korea) and approved by the Korea FDA for the treatment of chronic phase chronic myeloid leukemia (CML-CP) patients who have failed prior TKIs. We conducted the randomized, open-label, phase 3 study to assess the efficacy and safety of radotinib, as compared with imatinib, for the first-line treatment of newly diagnosed CML-CP. Methods Based on baseline demographics and Sokal risk score, 241 patients were randomized 1:1:1 to radotinib 300 mg twice dail

APA, Harvard, Vancouver, ISO, and other styles

27

Crump, M., B. Coiffier, E. D. Jacobsen, et al. "Oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in relapsed diffuse large B-cell lymphoma (DLBCL): Final results of a phase II trial." Journal of Clinical Oncology 25, no. 18_suppl (2007): 18511. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.18511.

Full text

Abstract:

18511 Background: Vorinostat (Zolinza™) is a histone deacetylase inhibitor (HDACI) approved in the US for the treatment of cutaneous manifestations in patients (pts) with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following 2 systemic therapies. Clinical responses with vorinostat have been reported in other lymphoma subtypes. Methods: Open-label, single-arm, nonrandomized Phase II trial of oral vorinostat 300 mg bid (initially 14 d/3 wks; amended to 3 d/wk) until disease progression or intolerable toxicity. Eligibility: measurable, relapsed/refractory

APA, Harvard, Vancouver, ISO, and other styles

28

Rimassa, Lorenza, Camillo Porta, Ivan Borbath, et al. "Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT)." Journal of Clinical Oncology 30, no. 15_suppl (2012): 4006. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4006.

Full text

Abstract:

4006 Background: Tivantinib (T) is a selective, oral inhibitor of c-Met, the tyrosine kinase receptor for hepatocyte growth factor involved in tumor cell migration, invasion, proliferation and angiogenesis. T has shown promising results in HCC in phase 1 studies as monotherapy and in combination with sorafenib. Methods: This multi-center RCT, enrolled pts with unresectable HCC, 1 failed systemic therapy, ECOG PS <2. Child-Pugh B-C were excluded. Pts were randomized 2:1 to oral T {360 mg bid (A), 240 mg bid (B)} or placebo (P), stratifying by PS and vascular invasion (VI). Treatment continue

APA, Harvard, Vancouver, ISO, and other styles

29

Sylvester, L., L. Laufman, K. Jabboury, et al. "Phase 2 study of MKC-1 in patients (pts) with metastatic breast cancer (MBC) who have failed prior therapy with an anthracycline (A) and taxane (T)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 11508. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.11508.

Full text

Abstract:

11508 Background: MKC-1 (previously Ro 31–7453) is a novel cell cycle inhibitor with significant in vitro and in vivo activity against a wide range of tumor cell lines, including multi-drug resistant cell lines. Proteins identified as binding targets of MKC-1 include microtubules (colchicine binding site) and members of the importin-β family (proteins that play a critical role in nuclear transport and spindle formation). Objective responses (ORs) were observed in heavily pre-treated breast and NSCLC pts (Trigo Perez ASCO’03 A62; Kurup ASCO’03 A2725) treated at a dose of 95 mg/m2 BID given 14 d

APA, Harvard, Vancouver, ISO, and other styles

30

Verstovsek, S., E. Atallah, D. Thomas, et al. "Dasatinib therapy for patients with Philadelphia-negative (ph-) myeloproliferative disorders (MPDs), including systemic mastocytosis." Journal of Clinical Oncology 25, no. 18_suppl (2007): 7086. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.7086.

Full text

Abstract:

7086 There are no curative medical therapies for Ph- MPDs. Over last several years several of the MPDs have been associated with the abnormal expression of selected tyrosine kinases (e.g. c-kit in SM) and others are suspected to be involved too. Therefore, we engaged in conducting a Phase II study with dasatinib, an orally available multi targeted kinase inhibitor, for patient with Ph- MPDs. Dasatinib is administered at 70 mg PO BID continuously (one month equals one cycle). Response is assessed every 3 cycles, and the therapy is discontinued in those without response after 6 cycles of therapy

APA, Harvard, Vancouver, ISO, and other styles

31

Smith, Michael, Robert Newton, Sherry Owens, et al. "28 Retrospective pooled analysis of epacadostat clinical studies identifies doses required for maximal pharmacodynamic effect in anti-PD-1 combination studies." Journal for ImmunoTherapy of Cancer 8, Suppl 3 (2020): A27. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0028.

Full text

Abstract:

BackgroundIDO1 is the initial rate-limiting enzyme in one breakdown pathway of tryptophan. It reduces tryptophan levels and generates metabolites (e.g., kynurenine [KYN]) that contribute to tumor-associated immune suppression. Epacadostat (EPA) is a novel, potent, selective, reversible inhibitor of IDO1 studied in clinical trials in combination with anti-PD-1 antibodies. Epacadostat-induced decreases in plasma KYN have been used as a pharmacodynamic measure of drug activity and have aided in dose selection for clinical studies. Despite encouraging signs of efficacy in combination with pembroli

APA, Harvard, Vancouver, ISO, and other styles

32

Sakamaki, Hisashi, Shin Fujisawa, Kensei Tobinai, et al. "Dasatinib (SPRYCEL®, BMS-354825) Phase-I/II Study of Patients with Chronic Myeloid Leukemia (CML) Resistant or Intolerant to Imatinib: Results of the CA180031 Study in Japan (Phase I Portion)." Blood 108, no. 11 (2006): 4809. http://dx.doi.org/10.1182/blood.v108.11.4809.4809.

Full text

Abstract:

Abstract Dasatinib (SPRYCEL®, formerly BMS-354825) is a potent, orally active, multi-targeted kinase inhibitor active against BCR-ABL and SRC family kinases. Studies outside Japan have demonstrated that dasatinib is highly effective in overcoming resistance and intolerance to imatinib (im), inducing durable cytogenetic and hematologic responses in this CML patient population. In establishing the dose for non-Japanese patients, the maximum tolerated dose failed to be reached and the 70-mg-twice-daily (BID) dose was determined to provide the optimal benefit-risk profile. Based on clinical experi

APA, Harvard, Vancouver, ISO, and other styles

33

Oloka-Onyango, J. "Poverty, Human Rights and the Quest for Sustainable Human Development in Structurally-Adjusted Uganda." Netherlands Quarterly of Human Rights 18, no. 1 (2000): 23–44. http://dx.doi.org/10.1177/092405190001800103.

Full text

Abstract:

In a bid to address the almost two decades of economic malaise and decline that Uganda had experienced in the 1970s and 1980s, Yoweri Museveni's National Resistance Movement adopted radical measures of economic adjustment under the tutelage of the World Bank and the International Monetary Fund. Although those measures resulted in significant economic growth – in GDP terms – this article argues that they failed to be conscious of basic principles of human rights relating to equality, non-discrimination and participation, and have consequently compounded the situation of poverty in the country.

APA, Harvard, Vancouver, ISO, and other styles

34

Von Mehren, M., P. Reichardt, P. G. Casali, et al. "A phase I study of nilotinib alone and in combination with imatinib (IM) in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST) - Study update." Journal of Clinical Oncology 25, no. 18_suppl (2007): 10023. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10023.

Full text

Abstract:

10023 Background: Nilotinib is a novel tyrosine kinase inhibitor (TKI) targeting KIT, PDGFR, and Bcr-Abl and inhibiting the proliferation of both IM-sensitive and -resistant cells in vitro. We report the results of a phase I study in GIST pts resistant to IM and other TKIs. Methods: Pts with progressive disease received nilotinib alone (400 mg p.o. bid) or escalating doses of nilotinib (200 mg qd, 400 mg qd, or 400 mg bid) in combination with IM (400 mg p.o. bid), or nilotinib 400 mg bid plus IM 400 mg qd. Pharmacokinetic (PK) analyses were performed. Tumor assessments (RECIST) were done every

APA, Harvard, Vancouver, ISO, and other styles

35

Annunziata, Mario. "Rapid and sustained molecular response to nilotinib in a patient with sub-optimal response to imatinib." Clinical Management Issues 5, no. 3S (2015): 25–28. http://dx.doi.org/10.7175/cmi.v5i3s.1122.

Full text

Abstract:

We describe here the case of a 40-years-old woman diagnosed as having chronic phase chronic myeloid leukemia and treated with standard dose of imatinib; the patient obtained the complete cytogenetic remission in 7 months, but she failed to achieve major molecular response (MMolR) after more than18 months of imatinib therapy. Sub-optimal response, defined according European LeukemiaNet guidelines, persisted despite of increasing imatinib dose to 600 mg daily. No BCR-ABL mutations were detected. Three months after switching to nilotinib 800 mg bid, the patient obtained MMolR. She experienced any

APA, Harvard, Vancouver, ISO, and other styles

36

de Totero, Daniela, Raffaella Meazza, Simona Zupo, et al. "Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells." Blood 107, no. 9 (2006): 3708–15. http://dx.doi.org/10.1182/blood-2005-09-3535.

Full text

Abstract:

Interleukin-21 (IL-21) is a member of the IL-2 cytokine family, which mediates proliferation or growth arrest and apoptosis of normal B cells, depending on their activation state. Here we demonstrate that surface IL-21 receptor (R) is expressed at variable levels by chronic lymphocytic leukemia (CLL) B cells freshly isolated from 33 different patients. IL-21R expression was up-regulated following cell stimulation via surface CD40. Therefore, IL-21 effects were more evident in CD40-activated CLL B cells. IL-21 induced an early signaling cascade in CLL B cells, which included JAK-1 and JAK-3 aut

APA, Harvard, Vancouver, ISO, and other styles

37

Kantarjian, Hagop M., Jorge Cortes, Philipp le Coutre, et al. "A Phase I Study of INNO-406 in Patients with Advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors." Blood 110, no. 11 (2007): 469. http://dx.doi.org/10.1182/blood.v110.11.469.469.

Full text

Abstract:

Abstract Background: INNO-406 is an orally available, dual Abl/Lyn kinase inhibitor that is up to 55-times more potent than imatinib in Bcr-Abl expressing cell lines. Numerous Bcr-Abl mutant proteins are sensitive to INNO-406 in vitro, including the F317L mutant. Unlike other second generation tyrosine kinase inhibitors (TKIs), INNO-406 demonstrates specific Lyn kinase activity with no or limited activity against other Src-family member kinases. Methods: In this phase I dose finding study, patients (pts) with imatinib-resistant or -intolerant Philadelphia (Ph+) chromosome-positive leukemias we

APA, Harvard, Vancouver, ISO, and other styles

38

Nanus, D. M., S. T. Tagawa, J. P. Dutcher, et al. "NCI 6896: A phase I trial of suberoylanilide hydroxamic acid (SAHA) and 13-cis retinoic acid in the treatment of patients with advanced renal cell carcinoma (RCC)." Journal of Clinical Oncology 29, no. 7_suppl (2011): 349. http://dx.doi.org/10.1200/jco.2011.29.7_suppl.349.

Full text

Abstract:

349 Background: Retinoid resistance in RCC inversely correlates with levels of intracellular retinol and retinyl esters suggesting that increasing intracellular levels of all-trans retinoic acid (RA) or enabling RA to become a more potent initiator of transcription will improve RA mediated anti-tumor effects. The combination of all-trans RA and a histone deacetylase (HDAC) inhibitor inhibited renal cancer cell proliferation and tumor growth in a xenograft model more than either drug alone. We performed a phase I clinical trial to evaluate the safety and preliminary efficacy of combining the or

APA, Harvard, Vancouver, ISO, and other styles

39

Chu, Quincy S., Derek J. Jonker, Diane M. Provencher, et al. "A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer." Journal of Clinical Oncology 38, no. 15_suppl (2020): 3581. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.3581.

Full text

Abstract:

3581 Background: LY2880070 (LY) is an oral, selective competitive inhibitor of checkpoint kinase 1 (Chk1). Chk1 inhibitors are known to increase the anti-tumor efficacy of agents such as gemcitabine (GEM), which induce replication stress. Synergy between these two agents has been applied to the clinical setting. Methods: This two-part, open-label multi-center study explores the safety, pharmacokinetics (PK), and anti-tumor activity of LY in patients with advanced or metastatic cancers. The primary objective of this study was to determine the maximum tolerated dose (MTD) for multiple escalating

APA, Harvard, Vancouver, ISO, and other styles

40

Kaempgen, Eckhart, Martina Schmid, Michael Erdmann, et al. "Predictable clinical responses to sorafenib in stage IV uveal melanoma." Journal of Clinical Oncology 30, no. 15_suppl (2012): e19032-e19032. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e19032.

Full text

Abstract:

e19032 Background: Uveal melanoma is an orphan disease with poor prognosis, once metastasized. There is currently no approved systemic treatment and all clinical trials so far failed to significantly improve OS in stage IV uveal melanoma patients (see results of the EORTC 18021 trial, abstract 95725). Sorafenib is a pleiotropic kinase inhibitor targeting tumor metabolism and related neoangiogenesis. Although sorafenib failed as monotherapy in metastasized melanoma, results from small phase II trials have indicated synergism with chemotherapy in some patients. We therefore offered compassionate

APA, Harvard, Vancouver, ISO, and other styles

41

Lay, Clarry H. "Athens' failed bid for the Olympic Games: The role of ego-involvement and affect on the collective self-esteem of Greek-Canadians." European Journal of Social Psychology 22, no. 4 (1992): 375–85. http://dx.doi.org/10.1002/ejsp.2420220406.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

CHEN, JUANJUAN, YABIN ZHANG, and ZHUJIA YIN. "EDUCATION PREMIUM IN THE ONLINE PEER-TO-PEER LENDING MARKETPLACE: EVIDENCE FROM THE BIG DATA IN CHINA." Singapore Economic Review 63, no. 01 (2018): 45–64. http://dx.doi.org/10.1142/s0217590818410023.

Full text

Abstract:

We study the education premiums in the online peer-to-peer (P2P) lending marketplace in which individuals bid on unsecured microloans applied by individual borrowers. Using more than 100,000 consummated and failed listings from the largest online P2P lending marketplace in China — Paipaidai.com, we examine whether higher education level lead to lower interest rates and lower risk of default. We find that controlling for other characteristics of borrowers, borrowing rates of borrowers with bachelor’s degrees is 0.141 percent higher than that of borrowers with associate’s degrees, and that femal

APA, Harvard, Vancouver, ISO, and other styles

43

ROUCOU, Xavier, Sylvie MONTESSUIT, Bruno ANTONSSON, and Jean-Claude MARTINOU. "Bax oligomerization in mitochondrial membranes requires tBid (caspase-8-cleaved Bid) and a mitochondrial protein." Biochemical Journal 368, no. 3 (2002): 915–21. http://dx.doi.org/10.1042/bj20020972.

Full text

Abstract:

In response to various apoptotic stimuli, Bax, a pro-apoptotic member of the Bcl-2 family, is oligomerized and permeabilizes the mitochondrial outer membrane to apoptogenic factors, including cytochrome c. Bax oligomerization can also be induced by incubating isolated mitochondria containing endogenous Bax with recombinant tBid (caspase-8-cleaved Bid) in vitro. The mechanism by which Bax oligomerizes under these conditions is still unknown. To address this question, recombinant human full-length Bax was purified as a monomeric protein. Bax failed to oligomerize spontaneously in isolated mitoch

APA, Harvard, Vancouver, ISO, and other styles

44

Driessen, Christoph, Dagmar Hess, Thomas Pabst, et al. "SAKK 65/08: A Phase I Trial of the HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib Identifies Nelfinavir As FDA Approved, Oral Drug that Inhibits the Proteasome and Induces Proteotoxic Stress in Vivo and has Potential Antimyeloma Activity." Blood 120, no. 21 (2012): 2956. http://dx.doi.org/10.1182/blood.v120.21.2956.2956.

Full text

Abstract:

Abstract Abstract 2956 Introduction: The HIV protease inhibitor nelfinavir has anti-myeloma activity in mice; it is approved at the 1250 mg bid dose for oral treatment of HIV. We performed a phase I dose escalation trial of nelfinavir in combination with bortezomib in patients with advanced hematologic malignancies. Methods: During cycle 1 (28 days), trial treatment consisted of 1 week nelfinavir monotherapy, followed by nelfinavir in combination with standard dose bortezomib (1.3 mg/m2i.v. day 8, 11, 15, 18), while cycles 2 and 3 (21 days each) consisted of 2 weeks nelfinavir in combination w

APA, Harvard, Vancouver, ISO, and other styles

45

Giles, Francis J., Philipp le Coutre, Kapil N. Bhalla, et al. "Nilotinib Therapy after Dasatinib Failure in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP), Accelerated Phase (AP) or Blast Crisis (BC)." Blood 110, no. 11 (2007): 1029. http://dx.doi.org/10.1182/blood.v110.11.1029.1029.

Full text

Abstract:

Abstract Background: Nilotinib and dasatinib are the next generation of tyrosine kinase inhibitors (TKIs) which have been developed for use in the treatment of imatinib-resistant/intolerant CML. Few therapeutic options are available for patients (pts) with CML who fail to benefit from or to tolerate first, imatinib, and then, a second generation TKI such as dasatinib and nilotinib. This phase II open-label study was designed to evaluate the safety and efficacy of nilotinib in such pts who either failed or were intolerant to imatinib and dasatinib. Methods: Nilotinib was administered at a dose

APA, Harvard, Vancouver, ISO, and other styles

46

Biondi, DO, David M., Jim Xiang, PhD, Mila Etropolski, MD, and Bruce Moskovitz, MD. "Tolerability and efficacy of tapentadol extended release in elderly patients ≥75 years of age with chronic osteoarthritis knee or low back pain." Journal of Opioid Management 11, no. 5 (2015): 393. http://dx.doi.org/10.5055/jom.2015.0289.

Full text

Abstract:

Objective: Management of chronic pain in elderly adult patients is often complicated by analgesic medication–related side effects. This post hoc analysis of pooled data evaluated the tolerability and analgesic efficacy of tapentadol extended release (ER) compared with oxycodone controlled release (CR) in elderly adult patients (≥75 years of age) with moderate to severe, chronic osteoarthritis knee or low back pain.Methods: Data were pooled from three similarly designed, randomized, double-blind, placebo- and active-controlled, phase 3 studies of tapentadol ER for moderate to severe, chronic os

APA, Harvard, Vancouver, ISO, and other styles

47

Ukpe, Aniekan Iboro. "Will EPAs Foster the Integration of Africa Into World Trade?" Journal of African Law 54, no. 2 (2010): 212–31. http://dx.doi.org/10.1017/s0021855310000057.

Full text

Abstract:

AbstractNew Economic Partnership Agreements were intended to replace the non-reciprocal EU-African, Caribbean and Pacific trade relationship by 1 January 2008, in a bid to further the development of African, Caribbean and Pacific countries under a WTO-compatible framework. African countries and regions failed to conclude any EPAs by that date due to scepticism about the deeper trade implications of EPAs. However, in a move that has seen the disintegration of Africa's EPA negotiating groups and compromised regional integration across the continent, many African countries broke ranks to initial

APA, Harvard, Vancouver, ISO, and other styles

48

Yates, Miriam S., and Tyler G. Okimoto. "Changing Beliefs About Female Leader Advancement Following the 2016 U.S. Presidential Election." Social Psychological and Personality Science 10, no. 4 (2018): 423–31. http://dx.doi.org/10.1177/1948550618766399.

Full text

Abstract:

Scholars have discussed the implications of positive leadership role models, including the impact of Barack Obama and Hillary Clinton’s political rise for aspiring leaders of underrepresented groups. However, there are also potential ramifications when those role models fail, shaping broader beliefs about the permeability of the glass ceiling. The current research tests this idea by evaluating the perceived promotability of male and female business leaders before ( n = 165) and following ( n = 159) the 2016 U.S. presidential election. Results indicated that the election result negatively affec

APA, Harvard, Vancouver, ISO, and other styles

49

Olusola Joseph Ajayi, Tolulope Sayo Toludare, and Yinusa Daniel Lamidi. "Design and fabrication of potters kick wheel for ceramic wares production." Global Journal of Engineering and Technology Advances 6, no. 1 (2021): 099–107. http://dx.doi.org/10.30574/gjeta.2021.6.1.0006.

Full text

Abstract:

An attempted to produce or fabricate a functional kick wheel have failed because some important principles guiding the fabrication of the kick wheel was neglected. Some of these are improper centered wheel head and low rotating force from the fly wheel. In this research, a design was generated in a bid to produce a functional kick wheel for pottery production using a marsonial wood for the skeletal part. The kick wheel was designed in such a way that the fly wheel and the centering can be self-controlled. Low cost of materials, reduced energy, lesser stress and conveniences during operation ar

APA, Harvard, Vancouver, ISO, and other styles

50

Jabbour, Elias, Hagop Kantarjian, Francis Giles, Susan O’Brien, and Jorge Cortes. "Treatment with Nilotinib for Patients with Chronic Myeloid Leukemia (CML) Who Failed Prior Therapy with Imatinib and Dasatinib." Blood 108, no. 11 (2006): 2171. http://dx.doi.org/10.1182/blood.v108.11.2171.2171.

Full text

Abstract:

Nilotinib (AMN107) is a selective Bcr-Abl kinase inhibitor which is aproximately 30-fold more potent than imatinib. Phase I and II studies confirmed the efficacy of nilotinib in imatinib-resistant CML. Dasatinib (BMS-354825) is a dual Src-Abl kinase inhibitor recently approved for the treatment of CML in all stages of the disease after imatinib failure. With the availability of more new tyrosine kinase inhibitors, one important question is the existence of cross-resistance between these new agents. To help answer this question, we analyzed the outcome of patients with CML who receive therapy w

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!